Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Sunken warship found off Danish coast after 225 years in ‘remarkable’ discovery - 2Can scientists detect life without knowing what it looks like? Research using machine learning offers a new way
- 3Yes, NASA's launching Artemis 2 astronauts to the moon on April Fools' Day. It's not a joke.
- 44 Jeep Models: Dominating Execution and Flexibility for Each Experience
- 5‘Everybody Loves Raymond: 30th Anniversary Reunion’ premiere date: How to watch, channel, time, cast and more
- Mojtaba Khamenei unconscious in Qom, not actually running Iran
- ‘Downton Abbey: The Grand Finale’ hits streaming: How to watch, cast info and everything you need to know
- Dave Coulier shares new cancer diagnosis 1 year after revealing previous diagnosis
- Golan resident convicted of spying for Iran after passing tank movement, missile-impact data
- Zelensky warns of imminent massive Russian attack on Ukraine
- Step in Style: A Survey of \Solace and Execution on the Track\ Running Shoes
- Nature's Treats: 10 Organic products That Lift Prosperity
- Five held on suspicion of planning attack on German Christmas market
- Support Your Investment funds with These Individual accounting Thoughts
